Cash Flow Statements

Group

Company

2009

2008

2009

2008

Note

£’000

£’000

£’000

£’000

Cash flows from operating activities

Net cash outflow from operations

28

(1,225)

(3,250)

(1,862)

(4,687)

Interest paid

(803)

(281)

(267)

(135)

Interest paid on finance leases

(45)

(41)

–

–

Taxation received/(paid)

1,603

(124)

–

–

Net cash used in operating activities

(470)

(3,696)

(2,129)

(4,822)

Investing activities

Interest received

456

67

1,214

1,472

Purchases of property, plant and equipment

(482)

(166)

–

–

Proceeds from sale of property, plant and equipment

27

47

–

–

Purchase of intangible assets

(2,005)

(3,907)

–

–

(Advances)/repayment of intra-group loans

–

–

(738)

1,419

Payment of contingent consideration re CS Dermatologie

(237)

(223)

(237)

(223)

Deconsolidation of Portugal subsidiary

(129)

–

–

–

Acquisition of subsidiary undertaking, net of cash acquired

(400)

(14)

–

(14)

Net cash used in investing activities

(2,770)

(4,196)

239

2,654

Financing activities

Repayments of obligations under finance leases

(219)

(156)

–

–

Proceeds from borrowings

3,866

5,370

2,771

1,780

Repayments of borrowings

(3,203)

(653)

(2,124)

(393)

Proceeds from issue of share capital

1,598

–

1,598

–

Share issue expenses

(63)

–

(63)

–

Net cash from financing activities

1,979

4,561

2,182

1,387

Net (decrease)/increase in cash, cash equivalents and bank overdrafts

(1,261)

(3,331)

292

(781)

Cash, cash equivalents and bank overdrafts at 1 July

(354)

2,604

(383)

398

Exchange gains on cash and bank overdrafts

18

373

–

–

Cash, cash equivalents and bank overdrafts at end of year

(1,597)

(354)

(91)

(383)

Cash, cash equivalents and bank overdrafts includes:

Cash and cash equivalents

88

1,052

17

21

Bank overdrafts

(1,685)

(1,406)

(108)

(404)

Cash, cash equivalents and bank overdrafts

(1,597)

(354)

(91)

(383)

The notes on pages 43 to 64 are an integral part of these consolidated financial statements.